Tilt Biotherapeutics lands EUR 4 million in funding
The Finnish oncolytic immunotherapy startup has raised almost ten million euros in funding to progress its lead candidate into phase I clinical trials.
Tilt Biotherapeutics, founded in 2013, enables tumour T-cell therapy by leveraging its patented technology utilising oncolytic viruses. The lead candidate, TILT-123, is a preclinical stage TNFα/IL2 armed oncolytic adenovirus.
The first phase I clinical trials are aimed to start early 2018. One of the trials, for which the funding raised will be used, will take place in two centres in Europe. It will address metastatic melanoma in combination with TILT-123 and TILs.